search
for
 About Bioline  All Journals  Testimonials  Membership  News  Donations


Journal of Cancer Research and Therapeutics
Medknow Publications on behalf of the Association of Radiation Oncologists of India (AROI)
ISSN: 0973-1482
EISSN: 1998-4138
Vol. 5, No. 2, 2009, pp. 130-132
Bioline Code: cr09033
Full paper language: English
Document type: Case Report
Document available free of charge

Journal of Cancer Research and Therapeutics, Vol. 5, No. 2, 2009, pp. 130-132

 en Dural sinus vein thrombosis in a patient with colon cancer treated with FOLFIRI/bevacizumab
Ozen, Alaattin; Cicin, Irfan; Sezer, Atakan; Uzunoglu, Sernaz; Saynak, Mert; Genchellac, Hakan & Karagol, Hakan

Abstract

The adverse effects of regimes in cancer treatment have forced us to change to new targeted therapy options. Understanding these side effects, which can lead to discontinuation of the new therapy strategies, will allow the clinical management of these side effects and result in continuing therapies with effective medications. Bevacizumab, which is an IgG1 antibody against vascular endothelial growth factor, has side effects such as proteinuria, hypertension, venous and arterial thromboembolic events, and hemorrhage. This is the first reported case of dural sinus vein thrombosis, during the treatment with bevacizumab.

Keywords
Bevacizumab, dural sinus vein, thrombosis

 
© Copyright 2009 Journal of Cancer Research and Therapeutics.
Alternative site location: http://www.cancerjournal.net/

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2020, Site last up-dated on 28-Nov-2020.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Internet Data Center of Rede Nacional de Ensino e Pesquisa, RNP, Brazil